Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is CARDIOME PHARMA CORP (CRME) a Good Stock to Buy?

Page 1 of 2

At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps can provide the best returns over the long term due to the fact that these companies are less efficiently priced and are usually under the radars of mass-media, analysts and dumb money. This is why we follow the smart money moves in the small-cap space.

One stock that registered an increase in popularity among smart money investors in our database last quarter is  CARDIOME PHARMA CORP (NASDAQ:CRME), in which eight funds held shares at the end of September.  The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Destination Maternity Corp (NASDAQ:DEST), Digirad Corporation (NASDAQ:DRAD), and Hydra Industries Acquisition Corp. (NASDAQ:HDRA) to gather more data points.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

doctor, patient, talking, man, male, physician, senior, older, consultant, medical, smiling, people, helpful, adult, desk, working, usa, american, practitioner, horizontal, taking

Monkey Business Images/Shutterstock.com

With all of this in mind, let’s take a peek at the latest action surrounding CARDIOME PHARMA CORP (NASDAQ:CRME).

How have hedgies been trading CARDIOME PHARMA CORP (NASDAQ:CRME)?

At the end of the third quarter, eight  funds tracked by Insider Monkey held long positions in this stock, compared to six funds a quarter earlier. On the other hand, there were seven hedge funds with a bullish position in CRME at the beginning of this year. So, let’s examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

HedgeFundSentimentChart

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Charles Clough’s Clough Capital Partners holds the number one position in CARDIOME PHARMA CORP (NASDAQ:CRME). Clough Capital Partners has a $9.6 million position in the stock. Coming in second is Justin John Ferayorni of Tamarack Capital Management, with a $6.9 million position; 2.2% of its 13F portfolio is allocated to the stock. Some other peers that are bullish contain Kris Jenner, Gordon Bussard, Graham McPhail’s Rock Springs Capital Management, Paul Hondros’s AlphaOne Capital Partners, and Hal Mintz’s Sabby Capital. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2